Platelet and coagulation factors in proliferative diabetic retinopathy

DQ BORSEY,* CV PROWSE,† RS GRAY,* J DAWES,‡ K JAMES,§ RA ELTON,||
BF CLARKE*

From the *Diabetic and Dietetic Department; †Blood Transfusion Service, Royal Infirmary, Edinburgh;‡MRC Immunoassay Team, Edinburgh; §Department of Surgery and ||Medical Computing and Statistics Unit, University of Edinburgh, Scotland

SUMMARY Plasma β-thromboglobulin, platelet factor 4, fibrinogen, fibrinopeptide A, antithrombin III, factor VIII related antigen, α₂-macroglobulin, platelet count, and total glycosylated haemoglobin were measured in three well matched groups of subjects: non-diabetic controls, diabetics without retinopathy, and diabetics with proliferative retinopathy. β-thromboglobulin and platelet factor 4 concentrations were significantly higher in the diabetics with retinopathy than in the controls and platelet factor 4 was also increased in the diabetics without retinopathy compared with controls. Fibrinogen concentration was raised in diabetics without retinopathy compared with controls, diabetics with retinopathy compared with controls, and diabetics with retinopathy compared with those without. Fibrinopeptide A concentration did not differ significantly between groups. Antithrombin III levels were increased in diabetics with retinopathy compared with controls, and in diabetics with retinopathy compared with those without. Factor VIII related antigen values were higher in both the diabetic groups when compared with the controls. Fibrinopeptide A concentration correlated with both β-thromboglobulin and platelet factor 4 in each of the three groups.

Haemostatic abnormalities in diabetes have been shown, although a hypercoagulable state has not been confirmed. These changes in platelet and coagulation function may be secondary to the development of microvascular disease and their role in the pathogenesis of retinopathy remains uncertain.

Patients with diabetes mellitus have significantly increased morbidity and mortality as a consequence of specific microvascular disease, which results in conditions such as retinopathy and nephropathy. Although the precise cause of these vascular complications remains uncertain, evidence is accumulating that an imbalance of the haemostatic mechanisms may be entailed in their initiation or propagation. Various abnormalities of platelet function and of coagulation in diabetes have been identified and recently reviewed.¹ The contradictory findings and conclusions of different research groups may be partially attributed to the heterogeneity of their diabetic patients, the poor matching of control groups, the non-standardisation of coagulation and platelet assays, and the uncertain importance of abnormal in vitro tests.

We have measured plasma concentrations of β-thromboglobulin, platelet factor 4, fibrinogen, fibrinopeptide A, antithrombin III, factor VIII related antigen, α₂-macroglobulin, platelet count, and total glycosylated haemoglobin in three well matched groups of subjects: non-diabetic controls, insulin dependent diabetics without retinopathy, and insulin dependent diabetics with proliferative retinopathy.

Patients and methods

Patients
We studied 20 healthy non-diabetic controls, 20 insulin dependent diabetics without ophthalmoscopic evidence of retinopathy, and 20 insulin dependent diabetics with proliferative retinopathy. Subjects in each group were individually matched for age, sex and, where applicable, duration of diab-
Table 1 Details of the subjects studied

<table>
<thead>
<tr>
<th>Normal</th>
<th>Diabetics</th>
<th>Diabetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>subjects</td>
<td>without</td>
<td>with</td>
</tr>
<tr>
<td></td>
<td>retinopathy</td>
<td>retinopathy</td>
</tr>
<tr>
<td>No of subjects</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>% male</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>35 ± 9</td>
<td>34 ± 9</td>
</tr>
<tr>
<td>Duration of diabetes (yr)</td>
<td>—</td>
<td>21 ± 7</td>
</tr>
<tr>
<td>Daily insulin dose (units)</td>
<td>—</td>
<td>62 ± 18</td>
</tr>
<tr>
<td>% ideal body weight*</td>
<td>—</td>
<td>101 ± 11</td>
</tr>
</tbody>
</table>

Values given as mean ± 1 SD.

METHODS

All diabetic fundi were examined ophthamoscopically through dilated pupils by one observer (BFC). Proliferative retinopathy was defined as the presence of neovascularisation. A single, 2 h postprandial venous blood sample was withdrawn into a polypropylene syringe, with minimal venous stasis, from resting subjects. The samples were analysed as detailed below:

β-thromboglobulin—radioimmunoassay of samples collected into anticoagulant mixture containing prostaglandin E₁.

Platelet factor 4—radioimmunoassay.

Fibrinopeptide A—radioimmunoassay of samples collected into aprotinin-heparin.

Fibrinogen (factor I)—clot turbidity assay of Ellis and Stransky.

Antithrombin III

(a) Antithrombin III activity—bioassay with chromogenic substrate using a commercially available kit (Boehringer-Mannheim Ltd).

(b) Antithrombin III antigen—electroimmunoassay method of Laurell using commercial antisera (Behringwerke).

Factor VIII related antigen—electroimmunoassay method of Laurell using commercial antisera (Behringwerke).

α₂-macroglobulin—standard Mancini gel diffusion method.

Results

The fibrinogen concentrations were higher in the diabetics with retinopathy than in the non-diabetic controls, and the platelet factor 4 values were significantly increased in both the diabetic groups when compared with the controls (diabetics with retinopathy p < 0-01; diabetics without retinopathy p < 0-05). A highly significant correlation between β-thromboglobulin and platelet factor 4 were seen in each of the three groups (controls and diabetics with retinopathy p < 0-001; diabetics without retinopathy p < 0-01).

The fibrinogen concentrations were higher in the
two diabetic groups than in the controls and also in the diabetics with retinopathy than in those without retinopathy.

There was no significant difference in fibrinopeptide A concentrations between the three groups. Within each group, however, fibrinopeptide A correlated significantly with β-thromboglobulin (p < 0.05) and platelet factor 4 (controls and diabetics without retinopathy p < 0.05; diabetics with retinopathy p < 0.01) (Figure).

Antithrombin III (activity and antigen) levels were significantly higher in the diabetics with retinopathy than in either of the other groups. There was a strong correlation between antithrombin III activity and antigen in each of the three groups (controls p < 0.01; diabetic groups p < 0.001). The concentration of α₂-macroglobulin was higher in the diabetics with retinopathy, than in those without but this difference was not significant. α₂-macroglobulin correlated with antithrombin III antigen only in the diabetics with retinopathy. There was no correlation between α₂-macroglobulin and antithrombin activity.

Concentrations of factor VIII related antigen were higher in both the diabetic groups than in the non-diabetic controls (p < 0.001).

The platelet count was higher in the non-retinopathic diabetics than in the control subjects (p < 0.05), but no other significant differences existed between groups.

Total glycosylated haemoglobin was higher in the diabetics with retinopathy than in those without (p < 0.05). The relation between glycosylated haemoglobin and the haemostatic factors studied was considered in each of the three groups: the only significant correlations were with fibrinogen in the control group (p < 0.001), with platelet factor 4 in the uncomplicated diabetics (p < 0.05), and with fibrinopeptide A and α₂-macroglobulin in the diabetics with retinopathy (p < 0.05).

---

**Table 2 Platelet and coagulation factors (median and range) in the three study groups and a comparison of paired measurements between groups**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Non-diabetic controls</th>
<th>Diabetics without retinopathy</th>
<th>Diabetics with retinopathy</th>
<th>Controls v Diabetics without retinopathy</th>
<th>Controls v Diabetics with retinopathy</th>
<th>Diabetics with retinopathy v those without</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-thromboglobulin (ng/ml)</td>
<td>31.5 (19.1-68.5)</td>
<td>44.9 (22.2-96.3)</td>
<td>51.5 (24.1-127.5)</td>
<td>NS</td>
<td>†</td>
<td>NS</td>
</tr>
<tr>
<td>Platelet factor 4 (ng/ml)</td>
<td>10.4 (10.0-52.0)</td>
<td>17.5 (8.5-72.6)</td>
<td>19.6 (6.7-63.7)</td>
<td>*</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Fibrinogen (g/l)</td>
<td>1.70 (1.04-2.93)</td>
<td>2.46 (1.56-3.46)</td>
<td>2.93 (1.85-5.70)</td>
<td>†</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Fibrinopeptide A (ng/ml)</td>
<td>1.64 (1.60-19.20)</td>
<td>2.82 (2.00-16.60)</td>
<td>2.80 (2.00-17.80)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Antithrombin III activity (%)</td>
<td>103 (82-119)</td>
<td>104 (92-122)</td>
<td>116 (92-132)</td>
<td>NS</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Antithrombin III antigen (%)</td>
<td>100 (76-126)</td>
<td>100 (87-121)</td>
<td>113 (87-126)</td>
<td>NS</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Factor VIII related antigen (%)</td>
<td>98 (72-140)</td>
<td>252 (126-460)</td>
<td>267 (142-400)</td>
<td>†</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>α₂-macroglobulin (mg%)</td>
<td>—</td>
<td>378 (192-641)</td>
<td>480 (187-696)</td>
<td>—</td>
<td>—</td>
<td>NS</td>
</tr>
<tr>
<td>Platelet count (×10⁹/l)</td>
<td>226 (106-284)</td>
<td>255 (104-420)</td>
<td>267 (126-350)</td>
<td>*</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Glycosylated haemoglobin (%)</td>
<td>6.6 (5.6-8.3)</td>
<td>10.7 (8.3-14.1)</td>
<td>11.7 (10.2-15.9)</td>
<td>†</td>
<td>†</td>
<td>*</td>
</tr>
</tbody>
</table>

NS = not significant. *p < 0.05, †p < 0.01, ‡p < 0.001.
Discussion

The published work provides a confusing picture of the importance of haemostatic abnormalities in the development of diabetic retinopathy. The poor matching of study groups, the non-standardisation of assays, the uncertain relevance of in vitro tests to in vivo function, and the inclusion of patients with coincident nephropathy and macroangiopathy have all contributed to this confusion. The subjects in our groups were individually matched for age, sex, and, where applicable, duration of diabetes, and all diabetics with nephropathy were excluded. In contrast to many previous studies, our two diabetic groups were chosen to represent the extremes of the "retinopathy spectrum"—namely, those without retinopathy and those with proliferative retinopathy. Unfortunately, the exclusion of patients with asymptomatic large vessel disease remains a problem since it necessitates unacceptable extensive and invasive investigation.

The platelet specific proteins β-thromboglobulin and platelet factor 4 are released together from α granules during platelet aggregation, and increased plasma levels may reflect enhanced in vivo platelet activation. Their precise biological functions remain uncertain. β-thromboglobulin may reduce prostacyclin generation in the vessel wall in vivo and thus allow a more sustained platelet-endothelial interaction. Platelet factor 4 has heparin neutralising activity and may neutralise any natural heparin like inhibitors of coagulation. It has been suggested that intensive release of platelet factor 4 modifies the surface properties of the platelet membrane and thereby accelerates the rate of formation of the fibrin network between platelets. A close correlation between the plasma levels of platelet factor 4 and β-thromboglobulin has been well described.

Both our diabetic groups had higher β-thromboglobulin concentrations than the controls, although this was significant only in patients with retinopathy. Both normal and increased plasma β-thromboglobulin concentrations have been reported in diabetes. The lack of a significant difference in β-thromboglobulin concentrations between the diabetics with retinopathy and those without is in keeping with a previous report from Edinburgh, but contrasts with work from other centres. The inconsistent findings of previous studies may be partially attributed to the use of different anticoagulant mixtures, sampling techniques, and assay methods and to the inclusion of diabetics with nephropathy. The latter is important since plasma β-thromboglobulin (but not platelet factor 4) concentrations are increased in the presence of renal impairment.

The platelet factor 4 results were, as expected, similar to those for β-thromboglobulin, although both diabetic groups had significantly higher levels than the non-diabetics. Platelet factor 4 concentration has been previously reported as both normal and increased in diabetics.

Fibrinopeptide A, which is cleaved from fibrinogen by thrombin, is a sensitive indicator of thrombin formation and the lack of a significant difference in concentrations between our three groups is evidence against activation of the coagulation system in diabetes. Our finding that fibrinopeptide A concentrations correlated with both β-thromboglobulin and platelet factor 4 concentrations suggests that thrombin may initiate the platelet release reaction. A close association between thrombin formation and the platelet release reaction in normal subjects has been previously noted in vitro and a correlation between fibrinopeptide A and β-thromboglobulin in diabetics has been reported by Burrows.

Fibrinogen is the immediate precursor of fibrin, influences plasma viscosity and is a necessary cofactor for ADP and epinephrine induced platelet aggregation. It is generally agreed that fibrinogen concentrations are increased in diabetic patients when compared with controls and several authors have, as in our study, shown higher concentrations in diabetics with retinopathy than in those without. This increase in fibrinogen concentration may be non-specific, perhaps in response to chronic vascular injury, rather than reflecting a hypercoagulable state. The higher concentrations of other acute phase reactants (such as haptoglobin, β-lipoprotein, and caeruloplasmin) in the serum of diabetic subjects lend support to this view. Our study has failed to confirm a reported correlation between glycosylated haemoglobin and fibrinogen in diabetics.

Antithrombin III is the major inhibitor of the activated coagulant enzymes XIIa, Xla, IXa, Xa, and thrombin. The risk of thrombo-embolic disease in patients with congenital antithrombin III deficiency is significantly increased. In a hypercoagulable state antithrombin III would be consumed and low circulating levels expected. Our findings of raised antithrombin III levels in those diabetics with retinopathy was therefore somewhat surprising. There have been reports of low, normal, and raised levels of antithrombin III in diabetics. Discrepancies between functional and immunological assays may account for some of these inconsistencies, although we found a strong correlation between antithrombin III activity and antigen. What then is the explanation of our findings? The raised
levels of antithrombin III may simply represent part of an acute phase reaction occurring subsequent to the development of retinopathy. Alternatively, an increase in antithrombin III may occur as a defence response to enhanced intravascular production of thrombin via a feedback mechanism increasing synthesis or decreasing catabolisim of antithrombin III.41

\(\alpha_2\)-macroglobulin is a further inhibitor of coagulation proteases which accounts for about a quarter of the total functional antithrombin III activity in the blood. Indeed, Elder et al40 attributed the raised levels of antithrombin III activity in their diabetics to an increase in \(\alpha_2\)-macroglobulin concentrations. We found no correlation between antithrombin III activity and \(\alpha_2\)-macroglobulin. Although it is generally accepted that \(\alpha_2\)-macroglobulin levels are higher in diabetics,31 42 43 the relation between retinopathy and \(\alpha_2\)-macroglobulin has remained uncertain because of other variables including age, duration of diabetes, metabolic control and nephropathy, which may influence \(\alpha_2\)-macroglobulin levels.42 44 Previous studies, which often failed to consider these factors, have reported both higher \(\alpha_2\)-macroglobulin concentrations in diabetics with retinopathy31 43 and comparable levels in retinopathies and non-retinopathies.42 Our results are in keeping with those of Gray et al,45 who found no significant difference in \(\alpha_2\)-macroglobulin levels between diabetics with retinopathy and those without when all the above variables were taken into account.

Factor VIII related antigen is a glycoprotein, higher oligomers of which are active in promoting platelet adhesion. It is found only in endothelial cells (where it is synthesised), platelets, and megakaryocytes.46 Von Willebrand's factor appears to be a property of factor VIII related antigen47 and these factors are associated in plasma with factor VIII coagulant activity. Our finding of increased factor VIII related antigen levels in diabetic patients is in keeping with previous reports33 48 49 and could result from enzymic degradation in the circulation of the factor VIII polymer and/or from greater endothelial synthesis and release of factor VIII related antigen.50 51 The lack of raised plasma fibrinopeptide A levels supports the latter explanation since in an enzymatically active environment one would expect increased thrombin formation. We found no significant difference in factor VIII related antigen values between diabetics with retinopathy and those without, although higher levels have been previously reported in diabetics with vascular disease.48 50 52

This study has shown certain platelet and coagulation abnormalities in diabetes, but the presence of a hypercoagulable state has not been confirmed. Several of our findings may be explained on the basis of a non-specific stress reaction in diabetics, possibly secondary to chronic vascular damage. Further studies, particularly of a prospective nature, are clearly indicated to determine whether the observed changes are causal or secondary to the vascular complications of diabetes mellitus.

References

18. Preston FE, Ward JD, Marcia BH, Porter NR, Timperley WR, O'Malley BC. Elevated \(\beta\)-thromboglobulin levels and circulat-

Borsey, Prowse, Gray, Dawes, James, Elton, Clarke

Requests for reprints to: Dr DQ Borsey, Ninewells Hospital, Ninewells, Dundee DD1 9SY, Scotland.